Evidence map›Paper›PMID 36232614›Full record

ArticleInternational journal of molecular sciences2022

Novel Strategies against Cancer: Dexibuprofen-Loaded Nanostructured Lipid Carriers.

Vaikunthavasan Thiruchenthooran, Marta Świtalska, Lorena Bonilla, Marta Espina, Maria Luisa García, Joanna Wietrzyk, Elena Sánchez-López, Anna Gliszczyńska

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vaikunthavasan ThiruchenthooranDepartment of Food Chemistry and Biocatalysis, Wrocław University of Environmental and Life Sciences, Norwida 25, 50-375 Wrocław, Poland.ORCID 0000-0002-4303-533X
Marta ŚwitalskaDepartment of Experimental Onclogy, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wrocław, Poland.
Lorena BonillaDepartment of Pharmacy, Pharmaceutical Technology and Physical Chemistry, University of Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-2043-2092
Marta EspinaDepartment of Pharmacy, Pharmaceutical Technology and Physical Chemistry, University of Barcelona, 08028 Barcelona, Spain.ORCID 0000-0003-1269-3847
Maria Luisa GarcíaDepartment of Pharmacy, Pharmaceutical Technology and Physical Chemistry, University of Barcelona, 08028 Barcelona, Spain.
Joanna WietrzykDepartment of Experimental Onclogy, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wrocław, Poland.ORCID 0000-0003-4980-6606
Elena Sánchez-LópezDepartment of Pharmacy, Pharmaceutical Technology and Physical Chemistry, University of Barcelona, 08028 Barcelona, Spain.ORCID 0000-0003-2571-108X
Anna GliszczyńskaDepartment of Food Chemistry and Biocatalysis, Wrocław University of Environmental and Life Sciences, Norwida 25, 50-375 Wrocław, Poland.ORCID 0000-0002-0218-6369

Funding

E.S-L want to acknowledge the support of the Grants for the Requalification of the Spanish Uni-versity System. The authors M.E., M.L.G and E.S-L want to acknowledge the Spanish Ministry of Science and Innovation (project reference PID2021-122187NB-C32). E.S-L want to acknowledge the support of the Grants for the Requalification of the Spanish Uni-versity System. The authors M.E., M.L.G and E.S-L want to acknowledge the Spanish Ministry of Science and Innovation (project reference PID2021-122187NB-C32).This work was supported by Wrocław University of Environmental and Life Sciences (Poland) under the Leading Research Groups support project from the subsidy increased for the period 2020-2025 in the amount of 2% of the subsidy referred to Art. 387 (3) of This work was supported by Wrocław University of Environmental and Life Sciences (Poland) under the Leading Research Groups support project from the subsidy increased for the period 2020-2025 in the amount of 2% of the subsidy referred to Art. 387 (3) of
6 · The paper itself

Abstract

The aim of this work was to design innovative nanostructured lipid carriers (NLCs) for the delivery of dexibuprofen (DXI) as an antiproliferative therapy against tumoral processes, and overcome its side effects. DXI-NLC samples were prepared with beeswax, Miglyol 812 and Tween 80 using high-pressure homogenization. A two-level factorial design 2

Indexed as

Breast NeoplasmsNanostructuresDrug CarriersHumansIbuprofenLipidsMaleParticle SizePolysorbatesdexibuprofenDrug CarriersIbuprofenLipidsPolysorbatesanticancer activitycytotoxicitydexibuprofendrug deliveryfactorial designnanostructured lipid carriers (NLCs)particle sizezeta potential

Identifiers

PMID36232614
PMCPMC9570096

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.